Through its effect on dopamine and serotonin signalling, treatment with Olanzapine can reduce psychotic symptoms and stabilise mood. It is used for adults with schizophrenia or bipolar disorder, including acute manic episodes and longer-term relapse prevention. Its calming effect can help with agitation and disturbed thinking, though weight and metabolic changes need active monitoring.
Olanzapine is an atypical antipsychotic tablet used in psychiatry for schizophrenia and bipolar disorder. It can reduce hallucinations, delusional beliefs, racing thoughts, severe agitation and disorganised behaviour.
Olanzapine on this page is supplied as oral tablets. The dose is decided individually, taking age, other medicines and health conditions into account. A prescriber may adjust treatment slowly to balance symptom control against sedation, appetite changes and other adverse effects.
Take the prescribed tablet regimen once daily at a consistent time, swallowing the tablet with water. Evening use is often selected when drowsiness is troublesome, although timing should follow the prescribed plan rather than a sudden self-directed change.
Olanzapine is an oral atypical antipsychotic tablet used in psychiatry. It affects dopamine and serotonin signalling to help reduce psychotic symptoms and stabilise mood in adults with schizophrenia or bipolar disorder. Treatment and dose are decided individually, with monitoring for drowsiness, appetite changes, weight and metabolic effects.
Olanzapine blocks selected dopamine and serotonin receptors in the brain. Dopamine blockade, mainly at D2 receptors, reduces excessive dopamine signalling linked with psychosis. Its activity at serotonin 5-HT2A receptors changes that balance and contributes to its effect on mood, thought processes and perception.
This receptor profile distinguishes atypical antipsychotics from older conventional antipsychotics, which tend to act more narrowly through dopamine blockade. Olanzapine can still cause movement-related adverse effects, yet these are generally less prominent than with many conventional agents when comparable clinical doses are used.
It also acts on histamine, muscarinic and alpha-adrenergic receptors. Those actions help explain why some people feel sleepy, hungry, dry-mouthed or light-headed when standing up. The same broad receptor activity that can help agitation may create trade-offs in day-to-day tolerability.
For bipolar disorder, it may be used during mania and as part of a plan to prevent further mood episodes.
Clinical guidelines from NICE include antipsychotic treatment within the management of schizophrenia and bipolar disorder. The choice of medicine is based on previous response, sleep disruption, physical health, other medicines and the side-effect profile most relevant to the individual [1].
Olanzapine may be considered when:
Poor outcomes often come from avoidable patterns rather than a complete lack of response.
Olanzapine is not for you if you have had a serious allergic reaction to olanzapine or any ingredient in the tablets. Signs of hypersensitivity can include widespread rash, hives, swelling of the lips or face, wheezing and difficulty breathing.
Extra caution is needed for people with diabetes, raised cholesterol, obesity, heart disease, low blood pressure, seizure history, glaucoma, prostate enlargement, severe constipation, liver impairment or Parkinsonian symptoms.
Pregnancy and breastfeeding also require an individual risk-benefit discussion because antipsychotic exposure near delivery may affect the newborn.
Olanzapine can impair alertness. Driving, cycling or operating machinery may be unsafe until the person knows how the tablets affect concentration and reaction time.
Drowsiness, increased appetite and weight gain are among the best-known effects of Olanzapine. Dry mouth, constipation, dizziness, fatigue and ankle swelling can also occur. Some people notice that early sedation lessens after the first weeks, while appetite changes may persist.
Metabolic effects deserve real attention. Olanzapine can raise blood glucose, triglycerides and cholesterol, and it can contribute to diabetes in susceptible people. Routine monitoring makes it possible to identify changes early rather than treating weight gain as an unavoidable part of psychiatric care. The MHRA and EMA product information describes somnolence, weight increase and metabolic changes among important treatment risks [3].
| Effect group | Symptoms and practical response |
|---|---|
| Common or dose-related effects | Sleepiness, increased appetite, dry mouth, constipation, dizziness and weight gain may improve with dose adjustment or supportive measures. |
| Metabolic effects | Increased waist size, thirst, frequent urination or unusual tiredness warrant assessment of weight, glucose and lipids. |
| Urgent reactions | Facial swelling, breathing difficulty, severe rash, high fever with muscle stiffness, fainting, seizures or uncontrolled movements need urgent medical attention. |
A rare but serious reaction is neuroleptic malignant syndrome. It can involve high fever, rigid muscles, confusion, sweating and a fast pulse. Tardive dyskinesia is another uncommon concern, causing repetitive movements of the face, tongue or limbs that may persist.
Antipsychotic selection is a balance of symptom pattern and tolerability. No option is automatically the best choice for every person.
| Treatment approach | Main trade-off |
|---|---|
| Olanzapine | Often helpful for psychosis, manic symptoms, agitation and disturbed sleep; weight gain, appetite increase and metabolic effects are key limitations. |
| Less sedating atypical antipsychotic approaches | May cause less sleepiness or weight gain for some people; restlessness, insomnia or other adverse effects may become more prominent. |
| Conventional antipsychotic approaches | Can be useful for certain symptoms; movement-related adverse effects such as stiffness, tremor and dystonia may occur more often. |
A past response to an antipsychotic is one of the strongest practical guides. If Olanzapine previously controlled severe symptoms but caused substantial weight gain, clinicians may weigh that benefit against metabolic monitoring, lifestyle support or an alternative treatment plan.
In clinical practice, prescribers usually discuss weight, waist measurement, blood pressure, blood glucose and lipids before or soon after starting Olanzapine. This is not paperwork for its own sake: weight gain and changes in glucose or cholesterol can develop while psychiatric symptoms are improving.
Doctors also look for a practical fit. Someone who already struggles with daytime sleepiness may need a different dosing time or a different treatment approach. WHO guidance on severe mental disorders supports combining medicine with psychosocial care, relapse planning and regular physical-health review rather than relying on tablets alone [2].
Treatment length depends on whether Olanzapine is being used for an acute episode, relapse prevention or a long-standing psychotic disorder. Long-term treatment can be appropriate when it continues to reduce relapse risk and physical health is monitored. NICE guidance published in 2014 supports ongoing antipsychotic treatment for many people with schizophrenia where the benefits outweigh adverse effects. Regular reviews should consider symptom control, functioning, weight, glucose and lipid results.
Sedation or calmer sleep may be noticed within the first days. Improvement in severe agitation can occur early, while clearer changes in hallucinations, delusional thinking or mood stability often take longer. The FDA prescribing information published in 2024 describes olanzapine as a treatment requiring regular daily use rather than occasional symptom relief. Early response should not prompt sudden dose changes without clinical direction.
Olanzapine tablets can be taken with food or without it. Food does not have a clinically meaningful effect on the amount absorbed. The EMA product information published in 2008 supports once-daily oral administration independent of meals. Choosing a consistent time is more useful than changing the routine around meals.
Olanzapine remains in the body for more than a day in many adults, which supports once-daily dosing. Its effects are maintained by taking tablets consistently, not by using an extra tablet during a difficult moment. The MHRA product information published in 2023 recognises that individual factors such as age, smoking status and interacting medicines can alter exposure. Missed doses can therefore affect some people more quickly than others.
Stopping suddenly may cause insomnia, sweating, nausea, anxiety, agitation or a return of psychotic or manic symptoms. A gradual reduction allows symptoms to be monitored and gives the brain time to adapt to changing receptor activity. WHO guidance issued in 2023 supports continuity of care and structured follow-up for severe mental disorders. A taper is tailored to the person’s psychiatric history and current stability.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I took Olanzapine for a manic episode and the first week left me very sleepy in the mornings. My thoughts slowed down after about two weeks and I was sleeping through the night again. Appetite was the part I had to work on because I started snacking much more.
I had been taking it for several months for schizophrenia. The voices became less intrusive and I could manage a normal evening routine, but I gained weight faster than expected. Blood tests and regular weigh-ins made the issue feel more manageable.
It helped with paranoia and I was less agitated, but I stopped it abruptly once because I thought I was fine. Sleep became poor within days and I felt on edge again. Restarting under supervision was much smoother than trying to manage the change alone.
